(25 days)
K780899A
Not Found
No
The summary describes a quality control material for immunofluorescent testing and does not mention any AI or ML components or functionalities.
No
Explanation: The device is described as an "unassayed quality control" used to monitor indirect immunofluorescent testing, which means it aids in the accuracy of diagnostic tests rather than treating a disease or condition itself.
No
Explanation: The device is described as an "unassayed quality control" used to "monitor indirect immunofluorescent testing." This indicates it's a control material for testing, not a device that directly diagnoses a patient's condition.
No
The device is a liquid control material, not a software application. It is a physical product used in laboratory testing.
Based on the provided information, the Liquichek™ Autoimmune Negative Control is an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use explicitly states it's for "monitoring indirect immunofluorescent testing for the analytes listed in this package insert." This indicates it's used in a laboratory setting to assess the performance of a diagnostic test.
- Device Description: It's prepared from human serum and used as a quality control. Quality controls are essential components of IVD testing to ensure accuracy and reliability.
- Input Imaging Modality: It's used with "Indirect immunofluorescent testing," which is a common technique in IVD laboratories for detecting antibodies.
- Predicate Device: The mention of a predicate device (K780899A; Kallestad ™ Autoantibody Negative Control Bio-Rad Laboratories) strongly suggests that this device is being compared to a previously cleared IVD device, a common practice in regulatory submissions for IVDs.
While the document doesn't explicitly state "IVD," the combination of its intended use in laboratory testing, its function as a quality control, and its association with a predicate IVD device clearly categorize it as an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The new Liquichek™ Autoimmune Negative Control is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the analytes listed in this package insert.
Product codes
82DHN
Device Description
This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ Autoimmune Negative Control. Product claims are as follows:
- Once the control is opened the analyte will be stable for 60 days when stored tightly capped at 2 to 8°C.
- The control is stable for 2 years when stored unopened at 2 - 8°C.
Real time studies will be ongoing to support the shelf life of this product. All supporting data is retained on file at Bio-Rad Laboratories.
Key Metrics
Not Found
Predicate Device(s)
K780899A
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.5100 Antinuclear antibody immunological test system.
(a)
Identification. An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).(b)
Classification. Class II (performance standards).
0
Bio-Rad Laboratories
Premarket Notification Section 510(k) for Liquichek™ Autoimmune Negative Control.
Summary of Safety and Effectiveness
Koay22w
Page 1 of 3
Summary of Safety and Effectiveness Liquichek™ Autoimmune Negative Control
1.0 Submitter
JAN 1 7 2003
Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 (949) 598-1200 Telephone: (949) 598-1555 Fax:
Contact Person
Yvette Lloyd Senior Requlatory Affairs Specialist Telephone: (949) 598-1465
Date of Summary Preparation
December 20, 2002
2.0 Device Identification
| Product Trade Name: | Liquichek™ Autoimmune Negative Control |
|---|---|
| --------------------- | ---------------------------------------- |
Antinuclear Antibody, Indirect Immunofluorescent, Common Name: Antigen, Control
| Classifications: | Class II |
|---|---|
| Product Code: | 82DHN |
| Regulation Number: | 21 CFR 866.5100 |
3.0 Device to Which Substantial Equivalence is Claimed
Kallestad ™ Autoantibody Negative Control Bio-Rad Laboratories
510 (k) Number: K780899A
Description of Device 4.0
This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.
1
Statement of Intended Use
5.0
The new Liquichek™ Autoimmune Negative Control is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the analytes listed in this package insert.
6.0 Comparison of the new device with the Predicate Device
This control is substantially equivalent to the following quality control material for autoimmune analysis that is currently in the market:
Kallestad™ Autoantibody Negative Control Bio-Rad Laboratories
510 (k) Number: K780899A
Table 1. Similarities and Differences between new and predicate device.
| Characteristics | Liquichek™ Autoimmune
Negative Control | Kallestad™ Autoantibody Negative
Control |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (New Device) | (Predicate Device) |
| Similarities | | |
| Intended Use | The Liquichek™ Autoimmune
Negative Control is intended for
use as an unassayed quality
control to monitor indirect
immunofluorescent testing for the
analytes listed in this package
insert. | The Autoantibody Negative Control
is a replacement reagent in the
Kallestad Fluorescent
Autoantibody test with mouse
kidney, mouse stomach/kidney,
Hep-2 cell line, or Crithidia luciliae
substrates. This test is an indirect
fluorescent antibody (IFA)
procedure for the detection and
semi-quantitation of human
antibodies. |
| Matrix | Human Serum | Human Serum |
| Storage
(Unopened) | 2°C to 8°C
until expiration date | 2°C to 8°C
until expiration date |
| Form | Liquid | Liquid |
| Differences | | |
| Stability
(Opened) | Once opened the analyte will be
stable for 60 days. | No open vial claims |
| Analyte | Antinuclear antibodies (ANA)
Speckled Pattern, Antinuclear
antibodies (ANA) Centromere
Pattern, Antinuclear antibodies
(ANA) Homogenous Pattern,
Antinuclear antibodies (ANA)
Mitotic Spindle Pattern. | No claims |
2
7.0 STATEMENT OF SUPPORTING DATA
Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ Autoimmune Negative Control. Product claims are as follows:
- 7.1 Once the control is opened the analyte will be stable for 60 days when stored tightly capped at 2 to 8°C.
- 7.2 The control is stable for 2 years when stored unopened at 2 - 8°C.
Real time studies will be ongoing to support the shelf life of this product.
All supporting data is retained on file at Bio-Rad Laboratories.
3
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human figures, one behind the other, forming a symbolic representation of health and human services.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Yvette Lloyd Senior Regulatory Affairs Specialist Bio-Rad Laboratories, QSD 9500 Jeronimo Road Irvine, California 92618-2017
JAN 1 7 2003
Re: K024220
Trade/Device Name: Liquichek™ Autoimmune Negative Control Regulation Number: 21 CFR § 866.5100 Regulation Name: Antinuclear Antibody Immunological Test System Regulatory Class: II Product Code: DHN Dated: December 20, 2002 Received: December 23, 2002
Dear Ms. Lloyd:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
4
Page 2 -
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
510 (k) Number (if known):_ КОДЧАДО
Device Name: Liquichek™ Autoimmune Negative Control
Indications for Use:
The Liquichek™ Autoimmune Negative Control is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the analytes listed in this package insert
(PLEASE DO NOT WRITE BELOW THE LINE-CONINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription use ✓ or
Over-the Counter use
Aflues for L. Bautista
(Division Sign-Off) Division of Clinical Laborat 510(k) Number -